Chongqing Zhifei Biological Products Co., Ltd.: Business Overview, Financials & Competitive Analysis
Chongqing Zhifei Biological Products Co., Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Established vaccine leader facing near-term margin pressure but positioned to benefit from China's vaccination initiatives and new product pipeline expansion. The company reported 2024 revenue of $3.6B (down 50.7% from 2023) and a market cap of $6.1B. Recent revenue decline and margin compression (-49.3% profit margin.
What is Chongqing Zhifei Biological Products Co., Ltd.'s industry? Chongqing Zhifei Biological Products Co., Ltd. (zhifeishengwu.com) operates in Biopharmaceuticals - Vaccine Manufacturing & Distribution. AskCyborg classifies Chongqing Zhifei Biological Products Co., Ltd. under Biopharmaceuticals - Vaccine Manufacturing & Distribution in its company registry.
Chongqing Zhifei Biological Products engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. Founded in 2002, the company has become a major biopharmaceut...
Cyborg Score thesis
Established vaccine leader facing near-term margin pressure but positioned to benefit from China's vaccination initiatives and...
Read the full analyst-debate transcript →Get the Latest Chongqing Zhifei Biological Products Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeChongqing Zhifei Biological Products Co., Ltd. Overview
Pro stress-test →Chongqing Zhifei Biological Products engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. Founded in 2002, the company has become a major biopharmaceutical player specializing in human vaccines across multiple therapeutic areas.
Strategic Profile
Pro stress-test →Zhifei operates an extensive service network supplying vaccines to over 30,000 vaccination points across 31 provinces in China. The company has built a proprietary cold chain system with real-time temperature monitoring, enabling safe long-distance vaccine transportation. This infrastructure provides competitive advantages in vaccine distribution across China's diverse healthcare landscape.
Competitive Landscape
Pro stress-test →Zhifei competes in China's biopharmaceutical and vaccine sector against both state-owned and private enterprises. As the first privately-run vaccine enterprise listed on China's ChiNext, Zhifei maintains competitive advantages through its extensive distribution network, cold chain infrastructure, and diversified vaccine portfolio. Competition includes state-backed vaccine producers and other private biotech firms developing vaccines for infectious diseases.
Industry Context
Chongqing Zhifei Biological Products Co., Ltd. operates in Biopharmaceuticals - Vaccine Manufacturing & Distribution.
Key facts
Founded: 2002 · Headquarters: Chongqing, China · Employees: 7,220 · Revenue: $3.6B (2024) · Market cap: $6.1B